Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 5

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 5
---
 taken any action that would permit this offering, or possession or distribution of this prospectus, in any jurisdiction where
action for that purpose is required, other than in the United States. Persons who have come into possession of this prospectus in a jurisdiction
outside the United States are required to inform themselves about and to observe any restrictions relating to this offering and the distribution
of this prospectus applicable to that jurisdiction.

We may also provide a prospectus
supplement or post-effective amendment to the registration statement to add information to, or update or change information contained
in, this prospectus. Any statement contained in this prospectus will be deemed to be modified or superseded for purposes of this prospectus
to the extent that a statement contained in such prospectus supplement or post-effective amendment modifies or supersedes such statement.
Any statement so modified will be deemed to constitute a part of this prospectus only as so modified, and any statement so superseded
will be deemed not to constitute a part of this prospectus. You should read both this prospectus and any applicable prospectus supplement
or post-effective amendment to the registration statement together with the additional information to which we refer you in the sections
of this prospectus titled “Where You Can Find More Information.”

This prospectus contains
summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for
complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred
to herein have been filed or will be filed as exhibits to the registration statement of which this prospectus is a part (the “Current
Registration Statement”), and you may obtain copies of those documents as described below under “Where You Can Find More Information.”

Certain monetary amounts,
percentages and other figures included herein have been subject to rounding adjustments. Accordingly, figures shown as totals in certain
tables and charts may not be the arithmetic aggregation of the figures that precede them, and figures expressed as percentages in the
text may not total 100% or, as applicable, when aggregated may not be the arithmetic aggregation of the percentages that precede them.

Unless the context otherwise
requires, all references herein to “CERo,” “we,” “us,” or “our” refer to the business
and operations of Legacy CERo and its consolidated subsidiaries prior to consummation of the Business Combination and to CERo and its
consolidated subsidiaries following the consummation of the Business Combination